The objectives of this application are three fold;renew the University of Florida (UF) Regional Clinical Center (UFRCC) for the Cardiovascular Cell Therapy Research Network (CCTRN);renew the successful Investigator Training Core;and apply for the Clinical Research Coordinator Skill Development Program. Cell therapy is an exciting concept for treatment of CV disease (CVD), but despite abundant preclinical and feasibility clinical studies the ability to translate findings to improve patient outcomes has lagged. To address this need, the UFRCC utilizes established programs in Stem Cell Biology/Regenerative Medicine (T32), Bone Marrow Transplant Center (part of NIH/NCI clinical research network), novel imaging resources, the CTSI, Advanced Heart Failure/ Transplant Program, and CV Clinical Trials Program. In addition to success in CCTRN-1, we have a long record of successful collaborations in multicenter NHLBI and other trials testing strategies to improve cardiac perfusion or function and evaluate clinical outcomes. For this renewal application, we propose that enhancing progenitor cell function will improve cardiac function and lead to better clinical outcomes. Our first protocol addresses enhancing progenitor cell homing after non-STEMI. Novel features include a method to enhance binding to selectins using fucosyltransferase and its substrate (ASC-101) to complete sialylated Lewis X formation. UFRCC investigators have shown that ASC-101 enhances vasculogenesis;it has received orphan drug status for bone marrow transplantation;and is manufactured at a UF GMP-compliant facility. The second protocol uses a novel cell population (CD34+) in high dose for CAD patients with heart failure (like FOCUS). Other novel features include: increasing Angl- 7 by exposure to a small molecule shown by UFRCC investigators to enhance cell migration and vasculogenesis;a new delivery catheter (BioCardia, Helical);and cell selection method (Miltenyi Biotec). Additional unique aspects of the UFRCC include collaborations with University of Puerto Rico, and industry. This work will improve our understanding of the role of cell therapy in CVD patients.
This is an application for a regional center to continue a collaborative network that will evaluate novel cardiovascular cellular therapies targeting our leading cause of death and major cause of disability. Two phase 1 clinical trials are proposed to provide new knowledge about the clinical role of cell therapy for heart attack and heart failure.
|Schutt, Robert C; Trachtenberg, Barry H; Cooke, John P et al. (2015) Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial. Circ Res 116:99-107|
|Petersen, John W; Pepine, Carl J (2014) The prevalence of microvascular dysfunction, its role among men, and links with adverse outcomes: noninvasive imaging reveals the tip of the iceberg. Circulation 129:2497-9|
|Krakoff, Lawrence R; Gillespie, Robert L; Ferdinand, Keith C et al. (2014) 2014 hypertension recommendations from the eighth joint national committee panel members raise concerns for elderly black and female populations. J Am Coll Cardiol 64:394-402|
|Traverse, Jay H; Henry, Timothy D; Pepine, Carl J et al. (2014) One-year follow-up of intracoronary stem cell delivery on left ventricular function following ST-elevation myocardial infarction. JAMA 311:301-2|
|Qi, Yanfei; Raizada, Mohan K (2014) Is natriuretic peptide receptor C a new target for hypertension therapeutics? Hypertension 63:661-2|
|Jarajapu, Yagna P R; Hazra, Sugata; Segal, Mark et al. (2014) Vasoreparative dysfunction of CD34+ cells in diabetic individuals involves hypoxic desensitization and impaired autocrine/paracrine mechanisms. PLoS One 9:e93965|
|Perin, Emerson C; Murphy, Michael; Cooke, John P et al. (2014) Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells. Am Heart J 168:667-73|
|Simari, Robert D; Pepine, Carl J; Traverse, Jay H et al. (2014) Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network. Circ Res 114:1564-8|
|Ascheim, Deborah D; Gelijns, Annetine C; Goldstein, Daniel et al. (2014) Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation 129:2287-96|
|Petersen, John W; Winchester, David E; Park, Ki et al. (2014) A training program in cardiovascular cell-based therapy: from the NHLBI Cardiovascular Cell Therapy Research Network. Regen Med 9:793-7|